China Meheco Group Co.,Ltd. (600056.SH) announced that its wholly-owned subsidiary, Hainan General Kangli Pharmaceutical Co., Ltd. ("Kangli Pharma"), recently received two "Drug Supplement Approval Notices" for Ganciclovir for Injection from the National Medical Products Administration (NMPA). The drug has passed the consistency evaluation for quality and efficacy of generic drugs.
Ganciclovir for Injection is primarily used to treat cytomegalovirus infections in immunocompromised patients with life-threatening or vision-threatening conditions, as well as to prevent cytomegalovirus infections in organ transplant recipients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments